Enrico Tagliafico

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7650973/publications.pdf

Version: 2024-02-01

87401 51423 8,760 159 40 90 citations h-index g-index papers 165 165 165 14092 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	PAX2/Renal Coloboma Syndrome Expresses Extreme Intrafamilial Phenotypic Variability. Nephron, 2023, 147, 120-126.	0.9	1
2	Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework. Diagnosis, 2022, 9, 115-122.	1.2	3
3	The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. Antioxidants, 2022, $11,113$.	2.2	6
4	BTK Inhibitors Impair Platelet-Mediated Antifungal Activity. Cells, 2022, 11, 1003.	1.8	7
5	The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches. International Journal of Molecular Sciences, 2022, 23, 5242.	1.8	7
6	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. ESMO Open, 2022, 7, 100459.	2.0	26
7	Characterization of New ATM Deletion Associated with Hereditary Breast Cancer. Genes, 2021, 12, 136.	1.0	7
8	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. Npj Breast Cancer, 2021, 7, 12.	2.3	9
9	Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. International Journal of Molecular Sciences, 2021, 22, 1906.	1.8	19
10	Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis. Npj Precision Oncology, 2021, 5, 4.	2.3	10
11	iVar, an Interpretation-Oriented Tool to Manage the Update and Revision of Variant Annotation and Classification. Genes, 2021, 12, 384.	1.0	21
12	The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study. Diagnostics, 2021, 11, 565.	1.3	7
13	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	2.5	8
14	A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib. Leukemia and Lymphoma, 2021, 62, 2018-2021.	0.6	2
15	Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers. Genes, 2021, 12, 616.	1.0	15
16	Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions. International Journal of Molecular Sciences, 2021, 22, 7693.	1.8	6
17	Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2021, 22, 9159.	1.8	7
18	How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring. Biomedicines, 2021, 9, 953.	1.4	6

#	Article	IF	CITATIONS
19	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. Journal of Hepatology, 2021, 75, 506-513.	1.8	40
20	Increased Plasma Levels of IncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. Cancers, 2021, 13, 4744.	1.7	9
21	Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. Cancers, 2021, 13, 4582.	1.7	28
22	Pre-existing cytopenia heralding de novo acute myeloid leukemia: uncommon presentation of NPM1-mutated AML in a single-center study. Leukemia Research, 2021, 111, 106747.	0.4	0
23	Genomic Analysis of Hematopoietic Stem Cell at the Single-Cell Level: Optimization of Cell Fixation and Whole Genome Amplification (WGA) Protocol. International Journal of Molecular Sciences, 2020, 21, 7366.	1.8	6
24	NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?. International Journal of Molecular Sciences, 2020, 21, 8975.	1.8	26
25	P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors. Cancer Research, 2020, 80, 3906-3919.	0.4	36
26	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncology, The, 2020, 21, 1455-1464.	5.1	52
27	BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy. Cancers, 2020, 12, 1252.	1.7	15
28	Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers. International Journal of Molecular Sciences, 2020, 21, 1081.	1.8	10
29	Changes in gene expression in human skeletal stem cells transduced with constitutively active Gsα correlates with hallmark histopathological changes seen in fibrous dysplastic bone. PLoS ONE, 2020, 15, e0227279.	1.1	7
30	Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. Scientific Reports, 2019, 9, 10558.	1.6	31
31	BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience. Annals of Oncology, 2019, 30, iii15.	0.6	0
32	MICAL2 is expressed in cancer associated neo-angiogenic capillary endothelia and it is required for endothelial cell viability, motility and VEGF response. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2111-2124.	1.8	14
33	Usefulness and Limitations of Comprehensive Characterization of mRNA Splicing Profiles in the Definition of the Clinical Relevance of BRCA1/2 Variants of Uncertain Significance. Cancers, 2019, 11, 295.	1.7	24
34	Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies. Cancers, 2019, 11, 193.	1.7	12
35	Gene expression profiles of human granulosa cells treated with bioequivalent doses of corifollitropin alfa (CFA) or recombinant human follicle-stimulating hormone (recFSH). Gynecological Endocrinology, 2019, 35, 623-627.	0.7	2
36	CXCR3 Identifies Human Naive CD8+ T Cells with Enhanced Effector Differentiation Potential. Journal of Immunology, 2019, 203, 3179-3189.	0.4	34

#	Article	IF	CITATIONS
37	Calreticulin Affects Hematopoietic Stem/Progenitor Cell Fate by Impacting Erythroid and Megakaryocytic Differentiation. Stem Cells and Development, 2018, 27, 225-236.	1.1	17
38	The early expansion of anergic NKG2A ^{pos} /CD56 ^{dim} /CD16 ^{neg} natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation. Haematologica, 2018, 103, 1390-1402.	1.7	61
39	Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. Leukemia, 2018, 32, 438-449.	3.3	26
40	ERBB2 and PI3KCA mutations in endocrine resistant breast cancer (BC). Annals of Oncology, 2018, 29, vi30.	0.6	0
41	Workload measurement for molecular genetics laboratory: A survey study. PLoS ONE, 2018, 13, e0206855.	1.1	6
42	Role of TGF â€Î²1/miRâ€382â€5p/ SOD 2 axis in the induction of oxidative stress in CD 34+ cells from primary myelofibrosis. Molecular Oncology, 2018, 12, 2102-2123.	2.1	19
43	Rare ceruloplasmin variants are associated with hyperferritinemia and increased hepatic iron in NAFLD patients: results from a NGS study. Journal of Hepatology, 2018, 68, S58-S59.	1.8	3
44	KLF4 Mediates the Effect of 5-ASA on the \hat{I}^2 -Catenin Pathway in Colon Cancer Cells. Cancer Prevention Research, 2018, 11, 503-510.	0.7	10
45	Calreticulin Ins5 and Del52 Mutations Impair Unfolded Protein and Oxidative Stress Responses in Hematopoietic Cells. Blood, 2018, 132, 4332-4332.	0.6	1
46	Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications. Oncotarget, 2018, 9, 31606-31619.	0.8	11
47	Genetic heterogeneity of primary hpobetalipoproteinemia reveald by the next generation sequencing (NGS). Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, e19-e20.	1.1	0
48	Molecular diagnosis of primary hypertriglyceridemias by next generation sequencing (NGS): Preliminary results and open questions. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, e33-e34.	1.1	0
49	Identification of miR-31-5p, miR-141-3p, miR-200c-3p, and GLT1 as human liver aging markers sensitive to donor-recipient age-mismatch in transplants. Aging Cell, 2017, 16, 262-272.	3.0	48
50	CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. Blood Cancer Journal, 2017, 7, 638.	2.8	27
51	Should pancreatic cancer be included in BRCA1/2 testing criteria?. Annals of Oncology, 2017, 28, v250.	0.6	0
52	Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis. International Journal of Molecular Sciences, 2017, 18, 145.	1.8	14
53	Family history of pancreatic cancer in BRCA1/2 testing criteria. Annals of Oncology, 2017, 28, vi46.	0.6	0
54	miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. Oncotarget, 2017, 8, 21380-21397.	0.8	13

#	Article	IF	Citations
55	Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells). PLoS ONE, 2017, 12, e0172430.	1.1	35
56	Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget, 2017, 8, 49451-49469.	0.8	49
57	Unravelling the Complexity of Inherited Retinal Dystrophies Molecular Testing: Added Value of Targeted Next-Generation Sequencing. BioMed Research International, 2016, 2016, 1-14.	0.9	47
58	Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Annals of Oncology, 2016, 27, 1867-1873.	0.6	109
59	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	2.0	80
60	Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. International Journal of Cancer, 2016, 138, 1657-1669.	2.3	6
61	Expression of \hat{l} 4-protocadherin is negatively regulated by the activation of the \hat{l}^2 -catenin signaling pathway in normal and cancer colorectal enterocytes. Cell Death and Disease, 2016, 7, e2263-e2263.	2.7	11
62	No Identical "Mesenchymal Stem Cells―at Different Times and Sites: Human Committed Progenitors of Distinct Origin and Differentiation Potential Are Incorporated as Adventitial Cells in Microvessels. Stem Cell Reports, 2016, 6, 897-913.	2.3	378
63	NF-YA splice variants have different roles on muscle differentiation. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 627-638.	0.9	29
64	MAF Induces Inflammatory Mediators Involved in the Pathogenesis of Primary Myelofibrosis. Blood, 2016, 128, 3132-3132.	0.6	0
65	MiR-494-3p Overexpression Leads to SOCS6 Downregulation and Supports Megakaryocytopoiesis in Primary Myelofibrosis CD34+ Hematopoietic Stem/Progenitor Cells. Blood, 2016, 128, 4272-4272.	0.6	0
66	Transcriptional Response of Human Neurospheres to Helper-Dependent CAV-2 Vectors Involves the Modulation of DNA Damage Response, Microtubule and Centromere Gene Groups. PLoS ONE, 2015, 10, e0133607.	1.1	17
67	Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. Oncologist, 2015, 20, 1001-1010.	1.9	85
68	Amplicon-based next-generation sequencing: an effective approach for the molecular diagnosis of epidermolysis bullosa. British Journal of Dermatology, 2015, 173, 731-738.	1.4	29
69	Abnormal expression patterns of <i>WT1-as, MEG3</i> and <i>ANRIL</i> long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. Leukemia and Lymphoma, 2015, 56, 492-496.	0.6	14
70	The barley Frost resistance-H2 locus. Functional and Integrative Genomics, 2014, 14, 85-100.	1.4	19
71	Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood, 2014, 123, 2157-2160.	0.6	115
72	DNA Microarray to Analyze Adenovirus–Host Interactions. Methods in Molecular Biology, 2014, 1089, 89-104.	0.4	3

#	Article	IF	Citations
73	Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia, 2014, 28, 1052-1059.	3.3	66
74	MafB is a downstream target of the IL-10/STAT3 signaling pathway, involved in the regulation of macrophage de-activation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 955-964.	1.9	27
75	Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1050-1057.	0.8	46
76	FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. BMC Cancer, 2014, 14, 396.	1.1	10
77	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood, 2014, 124, e21-e32.	0.6	105
78	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. Blood, 2014, 124, 405-405.	0.6	47
79	Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study. Blood, 2014, 124, 1867-1867.	0.6	0
80	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation. Annals of Hematology, 2013, 92, 1271-1280.	0.8	10
81	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	3.3	653
82	Differentiated Neuroprogenitor Cells Incubated with Human or Canine Adenovirus, or Lentiviral Vectors Have Distinct Transcriptome Profiles. PLoS ONE, 2013, 8, e69808.	1.1	20
83	Impact Of Prognostically Detrimental Mutations (ASXL1, EZH2, SRSF2, IDH1/2) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II. Blood, 2013, 122, 107-107.	0.6	2
84	Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis. Blood, 2013, 122, 1600-1600.	0.6	0
85	Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN. Blood, 2013, 122, 4099-4099.	0.6	0
86	Survival features of EBV-stabilized cells from centenarians: morpho-functional and transcriptomic analyses. Age, 2012, 34, 1341-1359.	3.0	6
87	Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression. Experimental Hematology, 2012, 40, 1043-1054.e6.	0.2	13
88	Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2012, 44, 1018-1026.	0.4	18
89	Transcriptional profiles underlying vulnerability and resilience in rats exposed to an acute unavoidable stress. Journal of Neuroscience Research, 2012, 90, 2103-2115.	1.3	16
90	Transplantation of Genetically Corrected Human iPSC-Derived Progenitors in Mice with Limb-Girdle Muscular Dystrophy. Science Translational Medicine, 2012, 4, 140ra89.	5.8	269

#	Article	IF	CITATIONS
91	The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories. Blood, 2012, 120, 1399-1399.	0.6	6
92	Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis Blood, 2012, 120, 2854-2854.	0.6	0
93	Gene expression profiling in MDS and AML: potential and future avenues. Leukemia, 2011, 25, 909-920.	3.3	64
94	Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) Journal of Clinical Oncology, 2011, 29, 507-507.	0.8	22
95	Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer Journal of Clinical Oncology, 2011, 29, 550-550.	0.8	1
96	c-myb supports erythropoiesis through the transactivation of KLF1 and LMO2 expression. Blood, 2010, 116, e99-e110.	0.6	95
97	Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica, 2010, 95, 1814-1822.	1.7	251
98	Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. Cancer Genetics and Cytogenetics, 2010, 200, 1-7.	1.0	2
99	Nfix Regulates Fetal-Specific Transcription in Developing Skeletal Muscle. Cell, 2010, 140, 554-566.	13.5	173
100	Integrated analysis of microRNA and mRNA expression profiles in physiological myelopoiesis: role of hsa-mir-299-5p in CD34+ progenitor cells commitment. Cell Death and Disease, 2010, 1, e28-e28.	2.7	33
101	Gene expression profiling of monocytes displaying herpes simplex virus 1 induced dysregulation of antifungal defences. Journal of Medical Microbiology, 2009, 58, 1283-1290.	0.7	8
102	Gene expression in grapevine cultivars in response to Bois Noir phytoplasma infection. Plant Science, 2009, 176, 792-804.	1.7	94
103	P.2.04 Microarray analysis in hippocampus of rats treated with escitalopram in the chronic escape deficit model of depression. European Neuropsychopharmacology, 2009, 19, S36-S37.	0.3	0
104	The homeobox gene Arx is a novel positive regulator of embryonic myogenesis. Cell Death and Differentiation, 2008, 15, 94-104.	5.0	28
105	Self-Renewing Osteoprogenitors in Bone Marrow Sinusoids Can Organize a Hematopoietic Microenvironment. Cell, 2008, 133, 928.	13.5	9
106	A balance between NF-Y and p53 governs the pro- and anti-apoptotic transcriptional response. Nucleic Acids Research, 2008, 36, 1415-1428.	6.5	77
107	Gene Expression Analysis of Angioimmunoblastic Lymphoma Indicates Derivation from T Follicular Helper Cells and Vascular Endothelial Growth Factor Deregulation. Cancer Research, 2007, 67, 10703-10710.	0.4	220
108	Intrinsic phenotypic diversity of embryonic and fetal myoblasts is revealed by genome-wide gene expression analysis on purified cells. Developmental Biology, 2007, 304, 633-651.	0.9	126

#	Article	IF	CITATIONS
109	Self-Renewing Osteoprogenitors in Bone Marrow Sinusoids Can Organize a Hematopoietic Microenvironment. Cell, 2007, 131, 324-336.	13.5	2,001
110	[300] HEPATIC EXPRESSION OF NUCLEAR RECEPTORS AND BILIARY TRANSPORTERS IN HUMAN CHOLESTEROL GALLSTONE DISEASE. Journal of Hepatology, 2007, 46, S119.	1.8	1
111	Transcriptional profiles in melanocytes from clinically unaffected skin distinguish the neoplastic growth pattern in patients with melanoma. British Journal of Dermatology, 2007, 156, 62-71.	1.4	14
112	Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nature Cell Biology, 2007, 9, 255-267.	4.6	899
113	Virally mediated MafB transduction induces the monocyte commitment of human CD34+ hematopoietic stem/progenitor cells. Cell Death and Differentiation, 2006, 13, 1686-1696.	5.0	67
114	Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia. Leukemia, 2006, 20, 1751-1758.	3.3	38
115	Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: focus on DNA repair genes. Leukemia, 2006, 20, 1978-1988.	3.3	31
116	Embryonic Stem-Derived Versus Somatic Neural Stem Cells: A Comparative Analysis of Their Developmental Potential and Molecular Phenotype. Stem Cells, 2006, 24, 825-834.	1.4	38
117	Identification of New p63 Targets in Human Keratinocytes. Cell Cycle, 2006, 5, 2805-2811.	1.3	41
118	Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy. Journal of Cell Science, 2006, 119, 5114-5123.	1.2	60
119	MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16995-17000.	3.3	75
120	Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1457-1462.	3.3	172
121	Gene Expression Profiling (GEP) of Myeloma (MM) Cells To Predict Attainment (near) Complete Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed MM Blood, 2006, 108, 245-245.	0.6	4
122	The Kinetic Status of Hematopoietic Stem Cell Subpopulations Underlies a Differential Expression of Genes Involved in Self-Renewal, Commitment, and Engraftment. Stem Cells, 2005, 23, 496-506.	1.4	45
123	Correlation between differentiation plasticity and mRNA expression profiling of CD34+-derived CD14â^' and CD14+ human normal myeloid precursors. Cell Death and Differentiation, 2005, 12, 1588-1600.	5.0	22
124	W15-P-001 Role of nuclear receptors in the molecular regulation of cholesterol homeostasis in cultured human hepatocytes. Atherosclerosis Supplements, 2005, 6, 96-97.	1.2	0
125	Msx2 and Necdin Combined Activities Are Required for Smooth Muscle Differentiation in Mesoangioblast Stem Cells. Circulation Research, 2004, 94, 1571-1578.	2.0	79
126	TGF \hat{l}^2 /BMP activate the smooth muscle/bone differentiation programs in mesoangioblasts. Journal of Cell Science, 2004, 117, 4377-4388.	1.2	70

#	Article	IF	CITATIONS
127	Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. Blood, 2004, 104, 3126-3135.	0.6	71
128	Requirement of the coiled-coil domains of p92c-Fes for nuclear localization in myeloid cells upon induction of differentiation. Oncogene, 2003, 22, 1712-1723.	2.6	12
129	Development of an IL-6 antagonist peptide that induces apoptosis in 7TD1 cells. Peptides, 2003, 24, 1207-1220.	1.2	14
130	Gene expression profile of Vitamin D3 treated HL60 cells shows an incomplete molecular phenotypic conversion to monocytes. Cell Death and Differentiation, 2002, 9, 1185-1195.	5.0	12
131	Physiological levels of 1alpha, 25 dihydroxyvitamin D3 induce the monocytic commitment of CD34+ hematopoietic progenitors. Journal of Leukocyte Biology, 2002, 71, 641-51.	1.5	31
132	Suppression of bile acid synthesis, but not of hepatic cholesterol 7α-hydroxylase expression, by obstructive cholestasis in humans. Hepatology, 2001, 34, 234-242.	3.6	31
133	A functionally active RARÎ \pm nuclear receptor is expressed in retinoic acid non responsive early myeloblastic cell lines. Cell Death and Differentiation, 2001, 8, 70-82.	5.0	6
134	Suppression of in vivo bile acid synthesis, but not of in vitro cholesterol 7α-hydroxylase expression, by biliary obstruction in humans. Journal of Hepatology, 2000, 32, 121.	1.8	0
135	Regulation ofobGene Expression: Evidence for Epinephrine-Induced Suppression in Human Obesity. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3309-3312.	1.8	57
136	Induction of a functional vitamin D receptor in all-trans-retinoic acid-induced monocytic differentiation of M2-type leukemic blast cells. Cancer Research, 1999, 59, 3803-11.	0.4	26
137	Antisense Inhibition of Bax mRNA Increases Survival of Terminally Differentiated HL60 Cells. Oligonucleotides, 1998, 8, 341-350.	4.4	9
138	Antisense Inhibition of c-fes Proto-oncogene Blocks PMA-Induced Macrophage Differentiation in HL60 and in FDC-P1/MAC-11 Cells. Blood, 1997, 89, 135-145.	0.6	29
139	Presence of a functional vitamin D receptor does not correlate with vitamin D3 phenotypic effects in myeloid differentiation. Cell Death and Differentiation, 1997, 4, 497-505.	5.0	12
140	Antisense Inhibition of c-fes Proto-oncogene Blocks PMA-Induced Macrophage Differentiation in HL60 and in FDC-P1/MAC-11 Cells. Blood, 1997, 89, 135-145.	0.6	3
141	Antisense inhibition of c-fes proto-oncogene blocks PMA-induced macrophage differentiation in HL60 and in FDC-P1/MAC-11 cells. Blood, 1997, 89, 135-45.	0.6	13
142	Bile acid structure and regulation of biliary protein secretion and composition in man. The Italian Journal of Gastroenterology, 1996, 28, 176-7.	0.1	2
143	All-trans-retinoic acid induces simultaneously granulocytic differentiation and expression of inflammatory cytokines in HL-60 cells. Experimental Hematology, 1995, 23, 117-25.	0.2	38
144	Role of c-fes protooncogene in myeloid differentiation. Cell Death and Differentiation, 1995, 2, 155-62.	5.0	2

#	Article	IF	Citations
145	Overexpression of C-kit in a Leukemic Cell Population Carrying a Trisomy 4 and its Relationship with the Proliferative Capacity. Leukemia and Lymphoma, 1993, 9, 495-501.	0.6	16
146	Inhibition of c-fes expression by an antisense oligomer causes apoptosis of HL60 cells induced to granulocytic differentiation Journal of Experimental Medicine, 1993, 178, 381-389.	4.2	60
147	Expression of interleukins 1, 3, 6, stem cell factor and their receptors in acute leukemia blast cells and in normal peripheral lymphocytes and monocytes. European Journal of Haematology, 1993, 50, 141-148.	1.1	28
148	Abundance of the primary transcript and its processed product of growth-related genes in normal and leukemic cells during proliferation and differentiation. Cancer Research, 1992, 52, 11-6.	0.4	99
149	Overexpression of the MPO gene occurring in a case of APL without unusual genotypic characteristics. Leukemia Research, 1990, 14, 735-742.	0.4	4
150	Noncoordinated expression of S6, S11, and S14 ribosomal protein genes in leukemic blast cells. Cancer Research, 1990, 50, 5825-8.	0.4	41
151	Differential effects of c-myb and c-fes antisense oligodeoxynucleotides on granulocytic differentiation of human myeloid leukemia HL60 cells. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 1990, 1, 543-8.	0.8	8
152	Detection of low abundance mRNA of myeloid specific genes in cells of acute and chronic lymphoid leukemias by cRNA hybridization. Leukemia, 1990, 4, 688-93.	3.3	6
153	Ratios between the abundance of messenger RNA and the corresponding protein of two growth-related genes, c-myc and vimentin, in leukemia blast cells. Cancer Research, 1990, 50, 1988-91.	0.4	12
154	Chronic myelogenous leukemia with typical clinical and morphological features can be Philadelphia chromosome negative and "bcr negative". Hematologic Pathology, 1990, 4, 67-77.	0.2	11
155	Cytogenetic and molecular studies in primary myelofibrosis. Cancer Genetics and Cytogenetics, 1989, 38, 101-113.	1.0	15
156	Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes. Leukemia, 1989, 3, 423-30.	3.3	19
157	Philadelphia-positive chronic myelogenous leukemia with typical bcr/abl molecular features and atypical, prolonged survival. Leukemia, 1989, 3, 538-42.	3.3	10
158	Myeloperoxidase gene expression in blast cells with a lymphoid phenotype in cases of acute lymphoblastic leukemia. Blood, 1988, 72, 873-876.	0.6	40
159	Myeloperoxidase gene expression in blast cells with a lymphoid phenotype in cases of acute lymphoblastic leukemia. Blood, 1988, 72, 873-876.	0.6	40